Interestingly, CIGB-258 and Tocilizumab showed similar efficacy in neutralizing the toxicity of CML (Figure 5 and Figure 6); they share several effects with an IL-6 inhibitor to reduce hepatic infiltration of inflammatory neutrophils and decrease serum TC and TG levels (Figure 7, Figure 8 and Figure 9). The gene discussed is IL6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.